Literature DB >> 2865153

Central nervous system side-effects with hydrophilic and lipophilic beta-blockers.

A Westerlund.   

Abstract

Previous investigations have suggested that hydrophilic beta-blockers, which appear at low concentrations in brain tissue, are less likely to produce CNS-related side-effects than are lipophilic beta-blockers, which occur at higher concentrations in the brain. The validity of this hypothesis was tested in a double-blind crossover study in which the hydrophilic beta-blocker atenolol was compared with the lipophilic agents metoprolol and propranolol, in 14 patients with a previous history of nightmares or hallucinations when treated with lipophilic beta-blockers. Nightmares or hallucinations were reported by all patients receiving lipophilic beta-blockers but by only three patients receiving atenolol. The total number of episodes was significantly lower (p less than 0.01) for patients receiving atenolol (8) than for those receiving lipophilic beta-blockers (54). It is concluded that atenolol is significantly less likely to provoke nightmares and hallucinations than are the lipophilic beta-blockers, metoprolol and propranolol. It seems likely that this finding is due to the differences in hydrophilicity amongst these drugs.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2865153     DOI: 10.1007/bf00543714

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  10 in total

1.  Long-term hypotensive effect of atenolol (ICI 66.082), a new beta-adrenergic blocking agent.

Authors:  L Hansson; B E Karlberg; H Aberg; A Westerlund; S Jameson; N C Henningsen
Journal:  Acta Med Scand       Date:  1976

2.  Direct evidence for an interaction of beta-adrenergic blockers with the 5-HT receptor.

Authors: 
Journal:  Nature       Date:  1977-05-19       Impact factor: 49.962

3.  Propranolol psychosis.

Authors:  H S Fraser; A C Carr
Journal:  Br J Psychiatry       Date:  1976-11       Impact factor: 9.319

Review 4.  The clinical importance of cardioselectivity and lipophilicity in beta blockers.

Authors:  J M Cruickshank
Journal:  Am Heart J       Date:  1980-08       Impact factor: 4.749

5.  Controlled study of atenolol in treatment of hypertension.

Authors:  L Hansson; H Aberg; B E Karlberg; A Westerlund
Journal:  Br Med J       Date:  1975-05-17

6.  Comparison between the acute hemodynamic effects and brain penetration of atenolol and metoprolol.

Authors:  P A van Zwieten; P B Timmermans
Journal:  J Cardiovasc Pharmacol       Date:  1979 Jan-Feb       Impact factor: 3.105

7.  Brain concentration of propranolol in relation to hypotensive effect in the rabbit with observations on brain propranolol levels in man.

Authors:  M G Myers; P J Lewis; J L Reid; C T Dollery
Journal:  J Pharmacol Exp Ther       Date:  1975-02       Impact factor: 4.030

8.  beta-Adrenoceptor agonists enhance 5-hydroxytryptamine-mediated behavioural responses.

Authors:  P J Cowen; D G Grahame-Smith; A R Green; D J Heal
Journal:  Br J Pharmacol       Date:  1982-06       Impact factor: 8.739

9.  Reduced brain serotonergic activity after repeated treatment with beta-adrenoceptor antagonists.

Authors:  H Hallberg; O Almgren; T H Svensson
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

10.  A comparison between atenolol and metoprolol in respect of central nervous system side effects.

Authors:  C A Kirk; R Cove-Smith
Journal:  Postgrad Med J       Date:  1983       Impact factor: 2.401

  10 in total
  14 in total

1.  Subjective symptoms and pharmacokinetics/dynamics of metoprolol CR in elderly subjects--a comparison with atenolol.

Authors:  E S Dimenäs; C G Dahlöf; B Heibel; R G Moore; B K Olofsson; G E Westergren; P W Lücker
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

2.  CNS-related subjective symptoms during treatment with beta 1-adrenoceptor antagonists (atenolol, metoprolol): two double-blind placebo controlled studies.

Authors:  E Dimenäs; C Dahlöf; B Olofsson; I Wiklund
Journal:  Br J Clin Pharmacol       Date:  1989-11       Impact factor: 4.335

3.  Pharmacological, physiological, and familial factors in propranolol-induced visions.

Authors:  Emmanuelle A D Schindler
Journal:  Neurol Clin Pract       Date:  2020-06

Review 4.  Adverse reactions and interactions with beta-adrenoceptor blocking drugs.

Authors:  R V Lewis; D G McDevitt
Journal:  Med Toxicol       Date:  1986 Sep-Oct

Review 5.  Formulary considerations in selection of beta-blockers.

Authors:  K C Yedinak
Journal:  Pharmacoeconomics       Date:  1993-08       Impact factor: 4.981

Review 6.  The Importance of Medicinal Chemistry Knowledge in the Clinical Pharmacist's Education.

Authors:  João Paulo S Fernandes
Journal:  Am J Pharm Educ       Date:  2018-03       Impact factor: 2.047

Review 7.  CNS-related (side-)effects of beta-blockers with special reference to mechanisms of action.

Authors:  W P Koella
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

8.  The effects of captopril vs atenolol on memory, information processing and mood: a double-blind crossover study.

Authors:  I J Deary; S Capewell; C Hajducka; A L Muir
Journal:  Br J Clin Pharmacol       Date:  1991-09       Impact factor: 4.335

9.  Influence of chronic beta-adrenoreceptor blocker treatment on melatonin secretion and sleep quality in patients with essential hypertension.

Authors:  T Rommel; L Demisch
Journal:  J Neural Transm Gen Sect       Date:  1994

10.  Changes in depressive status associated with topical beta-blockers.

Authors:  S Duch; C Duch; L Pastó; P Ferrer
Journal:  Int Ophthalmol       Date:  1992-09       Impact factor: 2.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.